We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sectra Ab | LSE:0A0L | London | Ordinary Share | SE0014609061 | SECTRA ORD SHS CLASS B |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 335.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
LINKÖPING, Sweden, Nov. 29, 2019 /PRNewswire/ -- Demand for the international medical imaging IT and cybersecurity company Sectra's (STO: SECT B) products increased and record-high order bookings were reported for the most recent 12-month period. A significant number of the orders pertain to long-term projects with new customers. In line with what has been previously stated, these projects had a negative impact on cash flow and earnings during the first half of 2019/2020. The projects' earnings and cash flows will improve as the systems are gradually put into service during the coming six months and onwards.
Six-month period, May-October 2019
Second quarter, August-October 2019
Torbjörn Kronander, President and CEO of Sectra AB, comments
"To summarize the first half of 2019/2020, more and more customers around the world are choosing Sectra's products and services. Our goal is to maintain this trust by helping customers give their patients better, more efficient care and increasing cybersecurity in critical social functions.
"The increase in order bookings during the period is primarily connected to Imaging IT Solutions, which for the first time exceeded SEK 2 billion on a rolling 12-month basis. Sectra's medical imaging solutions are comprehensive, personnel-intensive installation projects, and the period involved a build-up of delivery capacity to manage the large number of order bookings over the last year. These projects initially entail major costs, and only a small portion can be recognized as revenue for work in progress during the installation phase. As they transition into the operational phase, however, they will generate multiyear revenue streams with healthy margins. As we have stated previously, the investment-heavy first half of the year was in line with our plans and the costs will gradually shift into revenue and positive cash flow during the second half of 2019/2020.
"We are continuing to invest in future areas with significant growth potential. One of these areas is digital pathology, where we are growing within the European market, which has started to gain momentum. In the US, customers can currently only use our pathology solution for secondary review, since we still don't have FDA approval for primary review. For digital pathology, the FDA requires a complete chain consisting of scanner, IT system and monitor. To achieve this, we have initiated a collaboration with Leica Biosystems, a leading supplier of digital pathology scanners and other equipment, and in November Sectra submitted an application to the FDA based on Leica's scanner."
For further CEO comments and information, see the attached interim report.
Presentation of the interim report
A presentation will be held by Torbjörn Kronander, President and CEO of Sectra AB, and Mats Franzén, CFO of Sectra AB. The presentation will be held in English.
Time: November 29, 2019 at 10:00 a.m. (CET).
Follow online via investor.sectra.com/q2report2019 or
call:SE +46850558356
UK +443333009261
US +18338230586
A recorded version will also be available after the conference.
This information constitutes information that Sectra AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and/or the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:15 a.m. (CET) on November 29, 2019.
For further information, please contact:
Dr. Torbjörn Kronander
CEO and President Sectra AB
+46-(0)-705-23-52-27
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/sectra/r/sectra-s-six-month-interim-report-2019-2020--imaging-it-solutions--order-bookings-exceed-sek-2-billi,c2974304
The following files are available for download:
https://mb.cision.com/Main/1263/2974304/1152256.pdf | Sectra Q2 interim report 2019/2020 PDF |
https://news.cision.com/sectra/i/sectra-pathology,c2721120 | Sectra pathology |
https://news.cision.com/sectra/i/torbjorn-kronander--president-and-ceo-of-sectra-ab,c2721119 | Torbjörn Kronander, President and CEO of Sectra AB |
View original content:http://www.prnewswire.com/news-releases/sectras-six-month-interim-report-20192020-imaging-it-solutions-order-bookings-exceed-sek-2-billion-on-a-rolling-12-month-basis-300966754.html
SOURCE Sectra
Copyright 2019 PR Newswire
1 Year Sectra Ab Chart |
1 Month Sectra Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions